News
Yourlocation: Home > News > DRUG NEWS


Launched by Sun Pharma in USA for plaque psoriasis

Sun Pharma reported on 23 October 2018 the launch in the
USA of tildrakizumab (ILUMYA) as a therapy for moderate-tosevere
chronic plaque psoriasis in adults. Tildrakizumab, an
anti-IL-23p19 monoclonal antibody, is approved in the EU and
Australia for this indication. The antibody is under phase II/
III evaluation for psoriatic arthritis, ankylosing spondylitis and
axial spondyloarthritis.

Address:Room 301, Building 1, Wuxing Road 707#, Pudong New district, Shanghai Tel:021-50800372 18616876482 15006208799 Fax:021-50800327 Email:info@sepharm.com.cn Sales4@sepharm.com.cn
Copyright © Shanghai SE Pharm Co., Ltd

Reduce
Open